CoChat

Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer

Open access
Langston, Steven P., Grossman, Stephen, England, Dylan, Afroze, Roushan, Bence, Neil, Bowman, Douglas, Bump, Nancy, Chau, Ryan, Chuang, Bei-Ching, Claiborne, Christopher, Cohen, Larry, Connolly, Kelly, Duffey, Matthew, Durvasula, Nitya, Freeze, Scott, Gallery, Melissa, Galvin, Katherine, Gaulin, Jeffrey, Gershman, Rachel, Greenspan, Paul, Grieves, Jessica, Guo, Jianping, Gulavita, Nanda, Hailu, Shumet, He, Xingyue, Hoar, Kara, Hu, Yongbo, Hu, Zhigen, Ito, Mitsuhiro, Kim, Mi-Sook, Lane, Scott Weston, Lok, David, Lublinsky, Anya, Mallender, William, McIntyre, Charles, Minissale, James, Mizutani, Hirotake, Mizutani, Miho, Molchinova, Nina, Ono, Koji, Patil, Ashok, Qian, Mark, Riceberg, Jessica, Shindi, Vaishali, Sintchak, Michael D., Song, Keli, Soucy, Teresa, Wang, Yana, Xu, He, Yang, Xiaofeng, Zawadzka, Agatha, Zhang, Ji, Pulukuri, Sai M. · 2021 · Journal of Medicinal Chemistry
Cited by 203

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

SUMOylation is a reversible post-translational modification that regulates protein function through covalent attachment of small ubiquitin-like modifier (SUMO) proteins. The process of SUMOylating proteins involves an enzymatic cascade, the first step of which entails the activation of a SUMO protein through an ATP-dependent process catalyzed by SUMO-activating enzyme (SAE). Here, we describe the identification of TAK-981, a mechanism-based inhibitor of SAE which forms a SUMO-TAK-981 adduct as the inhibitory species within the enzyme catalytic site. Optimization of selectivity against related enzymes as well as enhancement of mean residence time of the adduct were critical to the identification of compounds with potent cellular pathway inhibition and ultimately a prolonged pharmacodynamic effect and efficacy in preclinical tumor models, culminating in the identification of the clinical molecule TAK-981.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.0c01491

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 203

Metadata

Authors
Langston, S. P., Grossman, S., England, D., Afroze, R., Bence, N., Bowman, D., Bump, N., Chau, R., Chuang, B.-C., Claiborne, C., Cohen, L., Connolly, K., Duffey, M., Durvasula, N., Freeze, S., Gallery, M., Galvin, K., Gaulin, J., Gershman, R., Greenspan, P., Grieves, J., Guo, J., Gulavita, N., Hailu, S., He, X., Hoar, K., Hu, Y., Hu, Z., Ito, M., Kim, M.-S., Lane, S. W., Lok, D., Lublinsky, A., Mallender, W., McIntyre, C., Minissale, J., Mizutani, H., Mizutani, M., Molchinova, N., Ono, K., Patil, A., Qian, M., Riceberg, J., Shindi, V., Sintchak, M. D., Song, K., Soucy, T., Wang, Y., Xu, H., Yang, X., Zawadzka, A., Zhang, J., & Pulukuri, S. M.
Venue
Journal of Medicinal Chemistry
Published
2021-02-25
Volume
64
Issue
5
Pages
2501-2520
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W3131360915
Cited by
203
References
5
FWCI
8.05
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer. https://app.cochat.ai/papers/10.1021/acs.jmedchem.0c01491
The paper
Langston, S. P., Grossman, S., England, D., Afroze, R., Bence, N., Bowman, D., Bump, N., Chau, R., Chuang, B.-C., Claiborne, C., Cohen, L., Connolly, K., Duffey, M., Durvasula, N., Freeze, S., Gallery, M., Galvin, K., Gaulin, J., Gershman, R., . . . Pulukuri, S. M. (2021). Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.0c01491

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.